- Type
- not stated
- Format
- Tabular commercial and production records: certificates of analysis per production batch (activity, purity, impurity panels), purchase-order and allocation registers, shipment and decay-correction records; delivered commercially as documents rather than as bulk data feeds today
- Volume
- Modest by record count but exceptionally dense: roughly 10^3-10^4 production batches and 10^3-10^5 commercial orders/allocations across a two-decade commercial relationship in a market measured in individual curies rather than tonnage (inferred: Ac-225 supply is campaign-based and the customer base is institutional and small, so volume is low while per-record value is unusually high)
- Users
- N/A — isotope producer and distributor, not a software or consumer platform, so there are no registered users in the usual sense. Scale is instead a customer network of clinical, research and radiopharmaceutical-development programmes, described on the page as 'extensive' and built over two decades by ITM; realistically low hundreds of institutional accounts.
- History
- 10 years
- Update frequency
- not stated
- Growth
- Active and expanding — the venture is explicitly scaling Canada-based Ac-225 production to meet stated urgent worldwide demand, has newly appointed named commercial leadership to drive adoption of next-generation targeted alpha therapies, and maintains an active conference presence; the whole framing is ramp-up rather than maintenance
- Launched
- ~2019-2022 for the Actineer venture and its Ac-225 commercialisation push (inferred: ITM is described as a founding partner that has led the venture's global commercial activities 'for two decades', which dates the underlying ITM radionuclide franchise to roughly 2005, while Ac-225-focused commercialisation and the currently-profiled leadership appointments are the recent layer)
- Delivery
- not stated
- Entity mapping
- not stated
- Sample
- not stated
- Point-in-time
- not stated
- Licence
- not stated